Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMarcel NijlandJLJennifer Lord‐BessenRKRajesh Kamalakar

Discussion

Loading...

Member takes

Overview

Randomized trial reports health-related quality of life in follicular lymphoma patients receiving epcoritamab plus rituximab, highlighting its safety profile.

Key Points

  • This analysis assesses the health-related quality of life in patients with relapsed/refractory follicular lymphoma treated with epcoritamab plus rituximab.
  • Randomized global phase 3 trial of Epcoritamab plus Rituximab versus Rituximab alone.
  • Patients completed patient-reported outcomes using the FACT-Lym instrument throughout treatment and follow-up.
  • Linear mixed-effect regression models analyzed the data.
  • 75% complete response in Epcoritamab group versus 43% in Rituximab alone.
  • 88% of patients experienced grade 3/4 adverse events with Epcoritamab.
  • No significant improvement in health-related quality of life scores was noted over time.

Cite This Study

Nijland et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e00ahttps://doi.org/10.1182/blood-2025-5370
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  2. 2Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025 · 14 citations
  3. 3Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma2026
  4. 4Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 2 citations
  5. 5EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R<sup>2</sup>) vs chemoimmunotherapy or R<sup>2</sup> in previously untreated follicular lymphoma.2024 · 7 citations